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Abstract
Background: When comparing active treatments, a non-inferiority (or one-sided equivalence) study design is often
used. This design requires the definition of a non-inferiority margin, the threshold value of clinical relevance. In
recent studies, a non-inferiority margin of 15 mm has been used for the change in endometriosis-associated pelvic
pain (EAPP) on a visual analog scale (VAS). However, this value was derived from other chronic painful conditions
and its validation in EAPP was lacking.
Methods: Data were analyzed from two placebo-controlled studies of active treatments in endometriosis,
including 281 patients with laparoscopically-confirmed endometriosis and moderate-to-severe EAPP. Patients
recorded EAPP on a VAS at baseline and the end of treatment. Patients also assessed their satisfaction with
treatment on a modified Clinical Global Impression scale. Changes in VAS score were compared with patients’ self-
assessments to derive an empirically validated non-inferiority margin. This anchor-based value was compared to a
non-inferiority margin derived using the conventional half standard deviation rule for minimal clinically important
difference (MCID) in patient-reported outcomes.
Results: Anchor-based and distribution-based MCIDs were-7.8 mm and-8.6 mm, respectively.
Conclusions: An empirically validated non-inferiority margin of 10 mm for EAPP measured on a VAS is appropriate
to compare treatments in endometriosis.
Introduction
Endometriosis is a common condition in women of
reproductive age that is characterized by the presence of
functional endometrium-like tissue outside the uterus
(e.g., the ovaries and other pelvic structures). Changes
in the number and size of such endometriotic lesions
were often used to assess the efficacy of treatment
options for endometriosis [1-4]. However, there is no
direct correlation between the extent of these lesions
and the severity of the symptoms experienced by the
patient [5-7]. Potential explanations for this lack of cor-
relation are that the level of pain induced by endome-
triosis might be determined by the depth of tissue
intrusion of a specific lesion, or that there may be a
direct interaction of endometriotic lesions and nerve
fibers [8,9]. Neither of these potential explanations can
be assessed by visual inspection during surgery and are
therefore not reflected in the respective scoring systems
for endometriosis severity [10,11].
Typical symptoms of endometriosis include dysmenor-
rhea, dyspareunia, and chronic pelvic pain [12-14]. Pain is
commonly considered the most relevant symptom and the
primary reason for treatment [14,15]. Different tools for
assessing pain in endometriosis, such as the visual analog
scale (VAS) or numerical rating scales, have been used in
the past. Recommendations on how to assess endometrio-
sis-related symptoms in a way that allows for comparison
of results between clinical trials have recently been pub-
lished [16]. However, publications on the validity of the
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still scarce and information on the psychometric proper-
ties of such tools in the indication of endometriosis are
generally lacking [17,18].
When comparing the efficacy of different active treat-
ments in endometriosis-associated pelvic pain (EAPP), a
non-inferiority-also called a one-sided equivalence-study
design is often used. This is because a new treatment
modality might provide a benefit for the patient (e.g.,
better tolerability and/or safety) even if it is not superior
to existing treatments with regard to efficacy [19-21].
The methodological principles for the non-inferiority
trial design are described in the International Confer-
ence on Harmonisation guideline E10 [22]. The design
of a non-inferiority study requires the a priori definition
of a non-inferiority margin, often called delta, which
describes the threshold value of clinical relevance.
There are clinical and statistical aspects to be consid-
ered when choosing a non-inferiority margin [23]. The
major clinical requirement for choosing a non-inferiority
margin is that any treatment difference smaller than the
non-inferiority margin should not be of clinical rele-
vance. The major statistical requirement for choosing a
non-inferiority margin is that the non-inferiority margin
is small enough to exclude the effect of placebo. The
focus of this paper is to empirically define the threshold
value of clinical relevance for EAPP measured on a VAS
that fulfils these criteria. It should be noted that the
definition of the clinically relevant threshold is indepen-
dent of the difference between a given treatment and
placebo. However, exclusion of the placebo effect needs
to be considered when applying the threshold value of
clinical relevance in a clinical trial.
The data for this paper derive from two recent rando-
mized, placebo-controlled clinical trials in EAPP. Both
trials used a very similar design, which is reported else-
where [24]. The patients recorded their EAPP on a VAS
at screening, baseline, during, and at the end of treatment
(week 12). At the end of the treatment, patients also
rated their satisfaction with treatment using a modifica-
tion of the Clinical Global Impression (CGI) scale-global
improvement item [25]. This simple and well-established
tool for the assessment of overall treatment effect was
used as an anchor for the definition of the minimal clini-
cally important difference (MCID) for EAPP.
Methods
Study design
These two international, randomized, double-blind, pla-
cebo-controlled studies investigated the efficacy and
safety of two different compounds in the treatment of
endometriosis.
Study 1 was conducted at 33 centers in Germany (n =
19), Italy (n = 8), and Ukraine (n = 6). Study 2 was
conducted at 28 centers in the Czech Republic (n = 4),
Denmark (n = 2), Spain (n = 6), Finland (n = 6), France
(n = 1), The Netherlands (n = 3), and Sweden (n = 6).
The study protocols were approved by local independent
Ethics Committees and all participants provided written
informed consent before study enrollment. The studies
were conducted in accordance with the amended ver-
sion of the Declaration of Helsinki and complied with
Good Clinical Practice.
Patients
W o m e na g e d1 8t o4 5y e a r s ,b e t w e e nm e n a r c h ea n d
menopause and in good general health except for endo-
metriosis, were eligible for study inclusion (Table 1).
Inclusion criteria included endometriosis stage I-IV,
according to revised American Society of Reproductive
Medicine (r-ASRM) scoring [11], which was assessed at
diagnostic laparoscopy within 12 months prior to study
baseline. Patients were required at both screening and
baseline to have an EAPP score of ≥ 30 mm (study 1) or
≥ 40 mm (study 2) on a VAS, where the anchor points
were 0 mm (representing absence of pain) and 100 mm
(indicating unbearable pain), without intervening mark-
ings (Figure 1).
Exclusion criteria included pregnancy or breastfeeding,
use of an intrauterine device, amenorrhea within 3
months of screening, signs or symptoms of therapy-
resistant endometriosis or need for near-term surgical
treatment of endometriosis, previous use of hormonal
agents (e.g., gonadotropin-releasing hormone agonists ≤
6 months before screening, progestins or danazol ≤ 3
months before screening, or oral contraceptives ≤ 1
month before screening), clinically relevant findings at
gynecological examination, or an abnormal cervical
cytological smear in the last 3 months.
Of 308 women with moderate-to-severe EAPP rando-
mized in the two studies, 281 provided data on the CGI
scale and change in EAPP.
Efficacy endpoints
The primary efficacy variable in both studies was the
absolute change in EAPP from baseline to the end of
Table 1 Patient demographics
Total number of patients, n (%) 281 (100)
Ethnic group, n (%)
Caucasian 278 (98.9)
Black 1 (0.4)
Asian 2 (0.7)
Age (years), mean (SD) 31.9 (6.4)
Weight (kg), mean (SD) 63.0 (10.8)
Body mass index (kg/m²), mean (SD) 22.8 (3.7)
SD, standard deviation
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by assessment of pain score on the VAS and intake of
supportive analgesic medication (ibuprofen tablets) for
pelvic pain.
Secondary efficacy variables included, among others, a
global assessment of efficacy by patients and investiga-
tors using the CGI scale-global improvement item [25]
(Table 2), which was applied at the end of treatment.
Statistical methods
Following the intent-to-treat approach, all randomized
patients who provided data were included in the ana-
lyses, regardless of possible protocol deviations.
EAPP was recorded by patients on a VAS before (at
screening and baseline), during, and at the end of treat-
ment. From these measurements, the individual absolute
change in EAPP was derived by subtracting the baseline
VAS score from the VAS score at end of treatment. At
the end of treatment, patients also rated their overall
satisfaction using the CGI scale-global improvement
item. For one patient, a missing assessment was replaced
by the corresponding physician’s assessment, because
these two ratings showed substantial agreement
(weighted  coefficient 0.69, n = 294; 95% confidence
interval [CI] 0.64-0.75), according to the definition of
Landis and Koch [26]. Missing VAS scores were not
imputed. In cases where patients dropped out prema-
turely, the last available measurement under treatment
was included in the analysis (last value carried forward
method).
All variables were analyzed by descriptive statistics,
either by absolute and relative frequencies for discrete
data, or by the number of non-missing observations,
mean, standard deviation, minimum, 25th percentile,
median, 75th percentile, and maximum for metric data.
Given that several categories on the seven-point GCI
scale were rarely ticked by the women (see Table 2), the
scale was aggregated to a three-point scale for further ana-
lyses. The entries “very much satisfied” and “much satis-
fied” were merged into “satisfied” and the entries “neither
satisfied nor dissatisfied” to “very much dissatisfied” were
merged into “undecided or worse”, whereas the category
“minimally satisfied” was left unchanged. These three
resulting categories were of approximately equal size and
there were no relevant differences in the VAS scores for
the categories merged. This one-sided approach was used
because the patients reporting themselves as “neither satis-
fied nor dissatisfied” showed, on average, a slight improve-
ment of their VAS scores and because this approach also
conserved the direction of the changes.
A bidirectional approach was additionally added as a
sensitivity analysis, with the assumption that patients
rate an increase in pain in the same way as a reduction
in pain. For this analysis, the CGI categories were
grouped into the three categories: “much change”
(including the categories “very much satisfied”, “much
satisfied”, “much dissatisfied”,a n d“very much dissatis-
fied”), “minimal change” (including the categories “mini-
mally satisfied” and “minimally dissatisfied”), and “no
change” (the remaining CGI category “neither satisfied
nor dissatisfied”). VAS score changes for satisfied
patients (who were assumed to have a reduction in
pain) were multiplied by-1 for this analysis.
Boxplots were drawn using the 10th and 90th percen-
tile as endpoints of the whiskers. Outlying observations
were also shown, using a dot as the plot symbol. A non-
parametric discriminant analysis with normal kernels
and unequal bandwidths [27] was performed. A one-way
analysis of variance (ANOVA) of the changes in VAS
score with factor grouped CGI category was performed
to estimate the mean differences and their 95% confi-
dence intervals. All statistical analyses were performed
using version 9.1 of SAS software [28], running under
Windows XP Professional.
Figure 1 The VAS. Patients record the severity of their pain on a VAS score from 0 mm to 100 mm.
Table 2 Subjects’ assessments on the CGI scale-global
improvement item (n, %)
CGI scale Aggregated CGI scale
Very much satisfied 18 (6.4) Satisfied 108
(38.4)
Much satisfied 90 (32.0)
Minimally satisfied 101
(35.9)
Minimally satisfied 101
(35.9)
Neither satisfied nor
dissatisfied
50 (17.8) Undecided or
worse
72 (25.6)
Minimally dissatisfied 14 (5.0)
Much dissatisfied 7 (2.5)
Very much dissatisfied 1 (0.4)
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Demography
Of the 308 women randomized in the two studies, 281
( 9 1 . 2 % )p r o v i d e dd a t ab o t ho nt h eC G Is c a l ea n do n
their change in pelvic pain and were included in this
analysis. Almost all of these women were Caucasian,
with a mean age of 32 years and a mean body mass
index of 23 kg/m² (Table 1).
CGI scale-global improvement item
The global efficacy assessment (Table 2) showed that
108 (38.4%) of the women were at least “much satisfied”,
101 (35.9%) were “minimally satisfied”,a n d2 2( 7 . 8 % )
were “minimally dissatisfied” or worse with their treat-
ment. The remaining 50 (17.8%) women rated them-
selves as “neither satisfied nor dissatisfied”.
VAS score
The mean (± standard deviation [SD]) EAPP decreased
during treatment from 58.9 ± 17.3 mm to 37.0 ± 23.6
mm on the VAS (Table 3). The mean change from base-
line was -22.9 ± 22.7 mm.
The relation between the VAS scores and patients’
CGI assessments is shown in Figure 2. As expected for
ah i g h l ys u b j e c t i v em e a s u r el i k ep a i n ,t h e r ew a ss o m e
overlap between the observed changes in the VAS
scores and the patients’ perceptions of how their EAPP
had changed. Women who were “satisfied” with their
treatment according to the CGI assessment had a mean
(± SD) change in VAS score of -36.9 ± 21.8 mm,
women who were only “minimally satisfied” had a
change of -19.5 ± 14.3 mm, and women who felt “unde-
cided or worse” had a change of -6.5 ± 20.7 mm (Table
4 ) .O na v e r a g e ,w o m e nw h of e l t“minimally satisfied”
had a VAS score that was 12.8 mm lower compared
with women who felt “undecided or worse”.U s i n gt h e
bidirectional approach, mean (± SD) changes in VAS
score were 33.9 ± 24.0 mm, 18.6 ± 16.3 mm, and 7.1 ±
19.5 mm for women reporting “much change”, “minimal
change”, and “no change”, respectively.
T h ea n c h o r - b a s e dM C I Di nE A P Pi sd e t e r m i n e db y
the value of VAS score change that best separates
women rating themselves as “undecided or worse” from
those rating themselves as “minimally improved”.T h i s
MCID of -7.8 mm was determined by non-parametric
statistical discriminant analysis. The best separation
between women rating themselves “improved” and those
rating themselves “minimally improved” was -27.6 mm
on the VAS. Using the bidirectional approach, the cutoff
values determined by discriminant analysis were 8.7 mm
and 28.2 mm. The difference between the means of “no
change” and “minimal change” determined by ANOVA
was 11.5 mm (95% CI 4.7-18.2) and the difference
between the means of “no change” and “much change”
was 26.8 mm (95% CI 20.0-33.6).
The distribution-based MCID is derived by halving the
standard deviation of the VAS scores at baseline.
According to empirical work by Norman et al. [29], this
generally provides a reliable estimate for an MCID for
patient-reported outcomes such as pain measurements.
The standard deviation of the VAS scores at baseline
was 17.3 mm (Table 3), yielding a distribution-based
MCID of -8.6 mm when considering that a reduction in
VAS score implies an improvement in EAPP.
Discussion
The VAS is among the most widely used pain scales
[30] and has been used in many conditions, including
acute and chronic pain of various origins [31-33]. The
validity and reliability of the VAS using anchor points of
0 mm (absence of pain) and 100 mm (unbearable pain)
have been demonstrated for different pain indications
[33] and values for the MCID have been established for
different types of pain; for example, in acute abdominal
pain, the MCID is reported as 13 mm (95% CI, 10-17)
[34,35], while MCID values appear generally to be lower
for chronic pain compared to acute pain [33].
The VAS was also commonly used in recent studies spe-
cifically designed to evaluate the pain associated with
endometriosis [36-45]. However, an empirical evaluation
of an MCID for this indication has been lacking. The aim
of this analysis was to derive an empirically validated
MCID for EAPP and compare it to the MCID reported for
other pain indications. We observed an MCID of approxi-
mately 10 mm for the change in EAPP measured by VAS,
irrespective of whether an anchor-based or a distribution-
based approach was used and irrespective of whether a
one-sided or a bidirectional approach was used.
A relatively large proportion of women in the two studies
reported that they were at least somewhat satisfied with
their treatment, although both studies used placebo as a
control group. This observation can be explained by the
Table 3 EAPP at baseline and end of treatment (VAS score, mm*) (n = 281)
Mean Standard deviation Minimum 25th percentile Median 75th percentile Maximum
Baseline 59.8 17.3 20 47 60 72 98
End of treatment 37.0 23.6 0 18 34 53 100
Change from baseline -22.9 22.7 -93 -36 -20 -8 67
*The VAS scores pain on a scale from 0 mm (absence of pain) to 100 mm (unbearable pain). A negative mean change in VAS score indicates a reduction in pain.
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well-designed studies in this indication [28,44].
Our empirical results for an MCID for EAPP mea-
sured on a VAS are comparable to the results for pain
measured by VAS in other settings, e.g., pain self-assess-
ment by patients with rheumatoid arthritis [31] or
physician-assigned pain scores across different types of
pain [32]. They are also in line with non-inferiority mar-
gins recently used in different chronic pain conditions,
including chronic low back pain [46], osteoarthritis [47],
and ankylosing spondylitis [48].
The limitations of our study were that we used only
one anchor and we measured the anchor only at the end
of the study. Hence the intra-subject variability of the
anchor-based MCID could not be determined. Additional
studies will be required to confirm that the results of our
analyses are generalizable to other patient populations
and other forms of endometriosis-associated pain.
The MCID of 10 mm for EAPP measured on a VAS
could also be used to define a non-inferiority margin for
the head-to-head comparison of two active treatments
in a non-inferiority trial. In this case, the statistical
requirement that the non-inferiority margin is limited
by the effectiveness of the reference treatment with
r e s p e c tt op l a c e b o[ 2 7 ]h a st ob ec o n s i d e r e d .F o ra
meaningful result, the non-inferiority margin must be
smaller than the difference between the reference active
treatment and placebo.
In conclusion, the empirically validated MCID for
EAPP measured on a VAS is 10 mm. This MCID could
also be used to define a non-inferiority margin for a
head-to-head comparison of two active treatments.
Figure 2 Change in VAS score categorized by patients’ assessments on the modified CGI scale-global improvement item. Boxplots are
drawn using the 10th and 90th percentiles as endpoints of the whiskers. Outlying observations are shown using a dot as the plot symbol.
Table 4 Change in EAPP (VAS score, mm*), categorized by subjects’ assessments on the aggregated CGI scale-global
improvement item
Subjects’ assessment n Mean Standard deviation of change Minimum 25th percentile Median 75th percentile Maximum
Satisfied 108 -36.9 21.8 -93 -50 -35 -22 20
Minimally satisfied 101 -19.5 14.3 -57 -28 -17 -10 8
Undecided or worse 72 -6.5 20.7 -69 -14 -5 5 67
*The VAS scores pain on a scale from 0 mm (absence of pain) to 100 mm (unbearable pain). A negative mean change in VAS score indicates a reduction in pain.
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